Targeting of Human Interferon Antagonists
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2014/063976, filed Jul 1, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,732,135 | Targeting of Human Interferon Antagonists In force · High confidence UsedRemaining | Université de Montpellier | In force | High confidence | ||
| US 10,072,059 | Targeting of Human Interferon Antagonists In force · High confidence | Université de Montpellier | In force | High confidence | ||
| US 10,947,288 | Targeting of Human Interferon Antagonists In force · High confidence | Université de Montpellier | In force | High confidence | ||
| US 12,741,998 | Targeting of Human Interferon Antagonists In force · Medium confidence | Université de Montpellier | In force | Medium confidence | ||
| Application 16/008,695 | Targeting of Cytokine Antagonists Abandoned Abandoned Mar 30, 2019 | Université de Montpellier | Abandoned | Abandoned Mar 30, 2019 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Universite de Montpellier.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.